Antibodies pp 227-247 | Cite as

Contract Manufacturing of Biopharmaceutical Grade Antibodies

  • Leo A. van der Pol
  • Douwe F. Westra


The success of over a dozen approved human antibodies on the therapeutic market supports the mature status of pharma-grade antibodies as group of biopharmaceuticals. With a significant higher number in clinical trials and the search for new recombinant proteins as a result of the human genome sequencing program it is expected that many more human antibodies will enter the market in years to come (Gura, 2002, Walsh, 2000).


Bovine Spongiform Encephalopathy Downstream Process Viable Cell Density Specific Production Rate Roller Bottle 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Adair, F. Ozanne, D., 2002, The immunogenicity of therapeutic proteins. BioPharm 15(2): 30–36.Google Scholar
  2. Chisti, Y., 2000, Animal-cell damage in sparged bioreactors. TibTech 18: 420–432.CrossRefGoogle Scholar
  3. Clayton, T., Jenkins, I., Steward, P., 1999, The improvement of aeration in 8000L animal cell culture vessels. In Animal Cell Technology: Products from Cells, Cells as Products (A. Bernard et al. eds.), Kluwer Academic Publ, p p.277–283.Google Scholar
  4. Fahrner, R.L., Whitney, D.H., Vanderlaan, M. and Blank, G.S., 1999, Performance comparison of Protein A affmity-chromatography sorbents for purifying recombinant monoclonal antibodies. Biotechnol. Appl. Biochem. 30: 121–128.PubMedGoogle Scholar
  5. Gura, T., 2002, Magic bullets hit the target. Nature 417: 584–586PubMedCrossRefGoogle Scholar
  6. Hahn, R., Schlegel, R. and Jungbauer, A., 2003, Comparision of protein A affinity sorbents. Journal of Chromatography B 790: 35–51.CrossRefGoogle Scholar
  7. Hesse, F., Wagner, R., 2000, Developments and improvements in the manufacturing of human therapeutics with mammalian cell cultures. TibTech 18: 173–180.CrossRefGoogle Scholar
  8. Iyer, H., Henderson, F., Cunningham, E., Webb, J., Hanson, J., Bork, C. and Conley, L., 2002, Considerations during development of a Protein A-based Antibody Purification Process. BioPharm 15(1): 14–53.Google Scholar
  9. Moran, E., McGowan, S.T., McGuire, J.M., Frankland, J.E., Oyebade, I.A., Waller, W., Archer, L.C., Morris, L.O., Pandya, J., Nathan, S.R., Smith, L., Cadette M.L., and Michalowski, J.T., 2000, A systematic approach to the validation of process control parameters for monoclonal antibody production in fed-batch culture of a murine myeloma. Biotechnology & Bioengeneering 69: 242–255.CrossRefGoogle Scholar
  10. van der Pol, L.A., Tramper, J., 1998, Shear sensitivity from a culture medium perspective. TibTech 16: 323–328.CrossRefGoogle Scholar
  11. Rathore, A., and Velayudhan, A., 2003, Guidelines for Optimization and Scale-Up in preparative chromatography. BioPharm 16(1): 34–42.Google Scholar
  12. Reichert, J.M., 2000, New biopharmaceuticals in the USA: trends in development and marketing approvals 1995-1999. TibTech 18: 364–369.CrossRefGoogle Scholar
  13. Sofer, G., 2003, Virus Inactivation in the 1990s-Part 4, culture media, biotechnology products, and vaccines. BioPharm 16(1): 50–57.Google Scholar
  14. The Biopharmaceutical Process Extractables Core Team, 2002, Evaluation of Extractables from Product-Contact Surfaces. BioPharm 15(12): 22–34.Google Scholar
  15. Walsh, G., 2000, Biopharmaceutical benchmarks. Nature Biotechnology 18: 831–833PubMedCrossRefGoogle Scholar
  16. Warner, T.N., and Nochumson, S., 2003, Rethinking the economics of chromatography. BioPharm 16(1): 58–60.Google Scholar

Copyright information

© Springer Science+Business Media New York 2004

Authors and Affiliations

  • Leo A. van der Pol
    • 1
  • Douwe F. Westra
    • 1
  1. 1.DSM Biologics Company BVGroningenThe Netherlands

Personalised recommendations